| Page 169 | Aplastic Anemia and MDS International Foundation

Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.

Author(s): 
Warlick ED
Primary Author: 
Warlick ED
Journal Title: 
Curr Opin Oncol
Original Publication Date: 
Mar 2010

PURPOSE OF REVIEW:

Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative therapy for myelodysplastic syndrome (MDS). Recent efforts to optimize the curative potential of transplant have focused on pretransplant therapy options, the use of predictive models to improve patient selection, and transplant modifications using reduced conditioning intensity. This review highlights strategies to optimize transplant for MDS and identifies unresolved questions.

Bone Marrow Diseases: 

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

Author(s): 
Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP
Primary Author: 
Shen L
Journal Title: 
J Clin Oncol
Original Publication Date: 
Dec 2009

PURPOSE:

The current classification systems of

Bone Marrow Diseases: 

Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.

Author(s): 
Bacher U, Haferlach C, Kröger N, Schnittger S, Kern W, Wiedemann B, Zander AR, Haferlach T
Primary Author: 
Bacher U
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Sep 2009

The rates of allogeneic stem cell transplantation (SCT) to treat the

Bone Marrow Diseases: 

Myelodysplastic syndromes: health care management considerations.

Author(s): 
Kogan AJ, Dunn JD
Primary Author: 
Kogan AJ
Journal Title: 
Manag Care
Original Publication Date: 
Nov 2009

Costs associated with treating cancers such as MDS are increasing as new medicines are developed and combination regimens gain hold. This trend presents an important challenge to MCOs who must respond to changing protocols and rising costs. Whereas the new oncology medications offer a unique opportunity to improve outcomes in patients with MDS, they also demand high financial outlay, which in turn necessitates adjustments in benefits programs.

Bone Marrow Diseases: 

Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.

Author(s): 
Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP
Primary Author: 
Jacobs NL
Journal Title: 
Am J Hematol
Original Publication Date: 
Mar 2010

The prognostic significance of the peripheral blood absolute

Bone Marrow Diseases: